Original language | English |
---|---|
Number of pages | 4 |
Journal | Hematological Oncology |
DOIs | |
Publication status | E-pub ahead of print - Nov 5 2020 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas. / Merli, Michele; Marino, Dario; Cencini, Emanuele; Rattotti, Sara; Fraenza, Costanza; Grossi, Paolo; Bianchi, Benedetta; Mora, Barbara; Sciarra, Roberta; Finotto, Silvia; Mecacci, Bianca; Passamonti, Francesco; Visco, Carlo; Arcaini, Luca.
In: Hematological Oncology, 05.11.2020.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas
AU - Merli, Michele
AU - Marino, Dario
AU - Cencini, Emanuele
AU - Rattotti, Sara
AU - Fraenza, Costanza
AU - Grossi, Paolo
AU - Bianchi, Benedetta
AU - Mora, Barbara
AU - Sciarra, Roberta
AU - Finotto, Silvia
AU - Mecacci, Bianca
AU - Passamonti, Francesco
AU - Visco, Carlo
AU - Arcaini, Luca
N1 - Funding Information: The Varese group was supported by grants of the Fondazione Regionale Ricerca Biomedica (FRRB), Milan, Italy (FRRB project no. 2015‐0042, genomic profiling of rare hematologic malignancies, development of personalized medicine strategies, and their implementation into the Rete Ematologica Lombarda clinical network), by Fondazione Matarelli (Milano, Italy) and AIL Varese ONLUS. Funding Information: Paolo Grossi has been paid scientific advisor for MSD, Biotest, Angelini, Nordic Pharma and received lecture fees from Vertex. Francesco Passamonti has been paid scientific advisor for Roche, Novartis, Gilead Sciences and received lecture fees from Novartis, Gilead Sciences. Luca Arcaini has been paid scientific advisor for Roche, Bayer, Celgene, Sandoz, Verastem and Gilead Sciences, received research funding from Gilead Sciences, received personal fees from Roche, Celgene, Gilead Sciences, EUSA Pharma and received lecture fees from Celgene. The other authors declare no potential conflict of interest. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/5
Y1 - 2020/11/5
UR - http://www.scopus.com/inward/record.url?scp=85096687482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096687482&partnerID=8YFLogxK
U2 - 10.1002/hon.2825
DO - 10.1002/hon.2825
M3 - Letter
C2 - 33150988
AN - SCOPUS:85096687482
JO - Hematological Oncology
JF - Hematological Oncology
SN - 0278-0232
ER -